CareDx Highlights HLA Typing Innovations at ASHI Annual Meeting
CareDx, Inc. (Nasdaq: CDNA), known as The Transplant Company™, announced today new data and product enhancements to be presented at the 50th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) in Anaheim, California, from October 21-25, 2024.…
BeiGene Gets CHMP Nod for TEVIMBRA® in Advanced Gastric and Esophageal Cancers
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued positive opinions recommending an extended authorization for TEVIMBRA® (tislelizumab)…
Endospan Completes Enrollment for NEXUS® Aortic Arch Stent Graft TRIOMPHE IDE Study
Endospan, a leader in endovascular solutions for the Aortic Arch, has announced the completion of enrollment for the primary arm of its TRIOMPHE Investigational Device Exemption (IDE) clinical study, which evaluates the safety and efficacy of the NEXUS® Aortic Arch…
Bruker Unveils $100 High-Accuracy Plasma Proteome for Glycoproteomics and Metaproteomics
At the 23rd Human Proteome Organization World Congress, Bruker Corporation (Nasdaq: BRKR) announced significant advancements in deep, unbiased, and high-sensitivity 4D-Proteomics. These developments enable robust, high-fidelity, large-scale studies while minimizing the inherent cross-talk issues associated with affinity high-plex technologies. A.…
NUCLIDIUM Begins Phase 1 Study of 61Cu Radiotracer in PSMA-Positive Prostate Cancer
NUCLIDIUM has announced the successful imaging of its first patient in a Phase 1 clinical trial for its radiotracer candidate, aimed at providing a safe and accurate diagnostic tool for prostate cancer. The radiotracer, 61Cu-NuriPro™ (61Cu-NODAGA-PSMA I&T), targets Prostate Specific…
ASDS 2024: Phase III READY-4 Data Show Long-Term Safety and Efficacy of Galderma’s Relfydess™
Galderma has announced new Phase III data from the READY-4 clinical trial, showcasing the long-term safety and efficacy of RelabotulinumtoxinA (Relfydess™) for treating frown lines and crow’s feet after repeated injections. The study met its primary and secondary endpoints, revealing…
Blue Lake and CyanVac Present Intranasal Vaccines at ISV Congress
Blue Lake Biotechnology, Inc., a clinical-stage company focused on intranasal vaccines using parainfluenza virus 5 (PIV5) vectors, and its affiliate CyanVac LLC, announced the presentation of positive interim pediatric clinical data for BLB201, their vaccine candidate targeting respiratory syncytial virus…
Seaport Therapeutics Secures $225 Million in Oversubscribed Series B Funding
Seaport Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative neuropsychiatric medicines, has successfully closed an oversubscribed $225 million Series B financing round. The round was led by General Atlantic, a prominent global growth investor, with participation from T. Rowe…
Agilent Transforms HPLC with Infinity III LC Series Launch
Agilent Technologies Inc. (NYSE: A) has unveiled its next-generation Agilent InfinityLab LC Series, featuring the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all available in biocompatible versions. These systems are the first…
Definitive Healthcare Launches Monocl Conferences for Biopharma and Medtech
Definitive Healthcare (Nasdaq: DH) has launched Monocl Conferences, a new solution aimed at improving conference planning and participation for life science organizations. This platform provides medical affairs, marketing, and conference planning teams with detailed, contextualized data on key conferences, helping…
PET-CT Scans: Enhancing Breast Cancer Outcomes
The World Health Organization reports that breast cancer was the most commonly diagnosed cancer among women in 157 out of 185 countries in 2022. That year, 2.3 million women were diagnosed with breast cancer, and tragically, 666,000 lost their lives…
Select Medical and SSM Health Partner for Inpatient Rehabilitation Hospital in Oklahoma City
Select Medical Corporation and SSM Health have announced a joint venture to establish the SSM Health Rehabilitation Hospital – Oklahoma City, a 50-bed inpatient rehabilitation facility located at 700 NW 7th Street. This hospital will incorporate SSM Health’s existing 12-bed…